We must now come to a uniform consensus regarding the descriptions of these risk groups in order to truly determine which treatments have the best oncologic efficacy, while minimizing overtreatment and optimizing patients’ quality of life.
Jen-Jane Liu, MD
Advertisement
Articles by Jen-Jane Liu, MD
Advertisement
Latest Updated Articles
- The Quest for an Evidence-Based Approach to Intermediate-Risk Prostate Cancer
Published: March 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
2
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
3
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
4
Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
5
